Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases

J. A. Neidhart, S. A. Anderson, J. E. Harris, J. J. Rinehart, J. Laszlo, F. H. Dexeus, L. H. Einhorn, D. L. Trump, P. W. Benedetto, R. L. Tuttle, R. V. Smalley

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

One hundred sixty-five patients were randomized to receive either interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of interferon given at daily doses of 3, 5, 20, 20, and 20 x 106 U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/m2 (later decreased to 5 mg/m2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.

Original languageEnglish (US)
Pages (from-to)832-837
Number of pages6
JournalJournal of Clinical Oncology
Volume9
Issue number5
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases'. Together they form a unique fingerprint.

  • Cite this

    Neidhart, J. A., Anderson, S. A., Harris, J. E., Rinehart, J. J., Laszlo, J., Dexeus, F. H., Einhorn, L. H., Trump, D. L., Benedetto, P. W., Tuttle, R. L., & Smalley, R. V. (1991). Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases. Journal of Clinical Oncology, 9(5), 832-837.